Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jack W Singer

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Leukemia & Lymphoma|September 21, 2018
Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosisKamal Menghrajani, Philip S Boonstra, Jessica A Mercer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 7, 2006
Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinibPaul La Rosée, Taiping Jia, Shadmer Demehri, et al.
Oncogene|March 1, 2005
Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitorsTeru Hideshima, Dharminder Chauhan, Kenji Ishitsuka, et al.
Cancer Research|December 18, 2003
Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myelomaTeru Hideshima, Dharminder Chauhan, Toshiaki Hayashi, et al.
British Journal of Haematology|November 17, 2015
Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDSRaya Mawad, Pamela S Becker, Paul Hendrie, et al.
The Lancet. Oncology|June 2, 2012
Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trialRuth Pettengell, Bertrand Coiffier, Geetha Narayanan, et al.
Molecular Pharmaceutics|November 19, 2009
Novel bis-platinum complexes endowed with an improved pharmacological profileLaura Gatti, Paola Perego, Roberto Leone, et al.
Leukemia|May 11, 2018
Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypesMona M Hosseini, Stephen E Kurtz, Sherif Abdelhamed, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2008
Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancerCorey J Langer, Kenneth J O'Byrne, Mark A Socinski, et al.
JAMA Oncology|March 10, 2018
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical TrialJohn Mascarenhas, Ronald Hoffman, Moshe Talpaz, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Leukemia & Lymphoma|September 21, 2018
Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosisKamal Menghrajani, Philip S Boonstra, Jessica A Mercer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 7, 2006
Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinibPaul La Rosée, Taiping Jia, Shadmer Demehri, et al.
Oncogene|March 1, 2005
Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitorsTeru Hideshima, Dharminder Chauhan, Kenji Ishitsuka, et al.
Cancer Research|December 18, 2003
Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myelomaTeru Hideshima, Dharminder Chauhan, Toshiaki Hayashi, et al.
British Journal of Haematology|November 17, 2015
Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDSRaya Mawad, Pamela S Becker, Paul Hendrie, et al.
The Lancet. Oncology|June 2, 2012
Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trialRuth Pettengell, Bertrand Coiffier, Geetha Narayanan, et al.
Molecular Pharmaceutics|November 19, 2009
Novel bis-platinum complexes endowed with an improved pharmacological profileLaura Gatti, Paola Perego, Roberto Leone, et al.
Leukemia|May 11, 2018
Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypesMona M Hosseini, Stephen E Kurtz, Sherif Abdelhamed, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2008
Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancerCorey J Langer, Kenneth J O'Byrne, Mark A Socinski, et al.
JAMA Oncology|March 10, 2018
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical TrialJohn Mascarenhas, Ronald Hoffman, Moshe Talpaz, et al.
Pageof 5